https://www.ft.com/content/455ef4e3-b870-4baa-9b05-977329e24356
Cancer vaccine using mRNA technology boosts survival, says Moderna
Data show combination with Merck’s immunotherapy drug reduced possibility of death in high-risk patients
www.ft.com
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R)
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial o
www.biospace.com
"Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone."
'스크랩 > 신문 기사' 카테고리의 다른 글
| South Koreans are the world's biggest spenders on luxury goods (0) | 2023.02.01 |
|---|---|
| Netflix will be next on Microsoft’s shopping list (0) | 2022.12.22 |
| 美, 인공태양 핵융합 발전… 무제한 에너지 생산 첫발 (0) | 2022.12.13 |
| Microsoft post success with tests of hydrogen backup generators for data centres (0) | 2022.07.30 |
| Britain approves Merck's COVID-19 pill in world first (0) | 2021.11.05 |